Selecta and Genovis enter exclusive license agreement

By The Science Advisory Board staff writers

October 21, 2021 -- Selecta Biosciences and Genovis have inked a strategic licensing agreement to advance a next-generation immunoglobulin G (IgG) protease for use in gene therapy and certain autoimmune diseases.

The partnership leverages Genovis' proprietary IgG protease, IdeXork (Xork), and Selecta's ImmTOR platform to enable the dosing of transformative gene therapies in patients with preexisting adeno-associated virus immunity and to treat certain IgG-mediated autoimmune diseases.

Under the agreement, Selecta obtains exclusive worldwide rights to Xork.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.